Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,560 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A single institution's experience with minimally invasive surgery for ovarian cancer, and a systematic meta-analysis of the literature.
Kamei Y, Kobayashi E, Nakatani E, Shiomi M, Sawada M, Kakuda M, Toda A, Nakagawa S, Hiramatsu K, Kinose Y, Takiuchi T, Miyoshi A, Kodama M, Hashimoto K, Kimura T, Ueda Y, Sawada K, Kimura T. Kamei Y, et al. Among authors: kodama m. Int J Clin Oncol. 2023 Jun;28(6):794-803. doi: 10.1007/s10147-023-02320-2. Epub 2023 Apr 28. Int J Clin Oncol. 2023. PMID: 37115425 Free PMC article. Review.
In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer.
Kodama M, Kodama T, Newberg JY, Katayama H, Kobayashi M, Hanash SM, Yoshihara K, Wei Z, Tien JC, Rangel R, Hashimoto K, Mabuchi S, Sawada K, Kimura T, Copeland NG, Jenkins NA. Kodama M, et al. Among authors: kodama t. Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7301-E7310. doi: 10.1073/pnas.1705441114. Epub 2017 Aug 15. Proc Natl Acad Sci U S A. 2017. PMID: 28811376 Free PMC article.
Plasminogen activator inhibitor-1 is an independent prognostic factor of ovarian cancer and IMD-4482, a novel plasminogen activator inhibitor-1 inhibitor, inhibits ovarian cancer peritoneal dissemination.
Nakatsuka E, Sawada K, Nakamura K, Yoshimura A, Kinose Y, Kodama M, Hashimoto K, Mabuchi S, Makino H, Morii E, Yamaguchi Y, Yanase T, Itai A, Morishige KI, Kimura T. Nakatsuka E, et al. Among authors: kodama m. Oncotarget. 2017 Sep 12;8(52):89887-89902. doi: 10.18632/oncotarget.20834. eCollection 2017 Oct 27. Oncotarget. 2017. PMID: 29163796 Free PMC article.
Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types.
Kobayashi M, Sawada K, Nakamura K, Yoshimura A, Miyamoto M, Shimizu A, Ishida K, Nakatsuka E, Kodama M, Hashimoto K, Mabuchi S, Kimura T. Kobayashi M, et al. Among authors: kodama m. J Ovarian Res. 2018 Sep 15;11(1):81. doi: 10.1186/s13048-018-0458-0. J Ovarian Res. 2018. PMID: 30219071 Free PMC article.
Lurbinectedin (PM01183), a selective inhibitor of active transcription, effectively eliminates both cancer cells and cancer stem cells in preclinical models of uterine cervical cancer.
Yokoi E, Mabuchi S, Shimura K, Komura N, Kozasa K, Kuroda H, Takahashi R, Sasano T, Kawano M, Matsumoto Y, Kodama M, Hashimoto K, Sawada K, Kimura T. Yokoi E, et al. Among authors: kodama m. Invest New Drugs. 2019 Oct;37(5):818-827. doi: 10.1007/s10637-018-0686-6. Epub 2018 Oct 30. Invest New Drugs. 2019. PMID: 30374654
Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells.
Yoshimura A, Sawada K, Nakamura K, Kinose Y, Nakatsuka E, Kobayashi M, Miyamoto M, Ishida K, Matsumoto Y, Kodama M, Hashimoto K, Mabuchi S, Kimura T. Yoshimura A, et al. Among authors: kodama m. BMC Cancer. 2018 Nov 5;18(1):1065. doi: 10.1186/s12885-018-4974-5. BMC Cancer. 2018. PMID: 30396333 Free PMC article.
Prostaglandin E2 produced by myeloid-derived suppressive cells induces cancer stem cells in uterine cervical cancer.
Kuroda H, Mabuchi S, Yokoi E, Komura N, Kozasa K, Matsumoto Y, Kawano M, Takahashi R, Sasano T, Shimura K, Kodama M, Hashimoto K, Sawada K, Morii E, Kimura T. Kuroda H, et al. Among authors: kodama m. Oncotarget. 2018 Nov 20;9(91):36317-36330. doi: 10.18632/oncotarget.26347. eCollection 2018 Nov 20. Oncotarget. 2018. PMID: 30555631 Free PMC article.
1,560 results